Her2/Neu brain mets

I am trying to identify literature which reports the incidence of leptomeningeal dissemination (LM) in patients with resected HER2/neu amplified brain mets in the posterior fossa. Can anyone help point me in the right direction?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums

Related Links:

Publication date: Available online 10 August 2020Source: Pathology - Research and PracticeAuthor(s): Jing Zhao, Uma Krishnamurti, Chao Zhang, Jane Meisel, Zhimin Wei, Aili Suo, Ritu Aneja, Zaibo Li, Xiaoxian Li
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Abstract Single domain antibody fragments (sdAbs) exhibit a rapid tumor uptake and fast blood clearance amenable for labeling with 18F (t½ = 110 min) but suffer from high kidney accumulation. Previously, we developed a method for 18F-labeling of sdAbs via trans-cyclooctene (TCO)-tetrazine (Tz) inverse electron demand Diel's Alder cycloaddition reaction (IEDDAR) that incorporated a renal brush border enzyme (RBBE)-cleavable linker. Although>15 fold reduction in kidney activity levels was achieved, tumor uptake was compromised. Here we investigate whether replacing the [18F]AlF-NOTA moiety with [18F]...
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Tags: Bioorg Med Chem Source Type: research
Condition:   Breast Cancer Metastatic Intervention:   Drug: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C Sponsor:   Dizal Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-negative Gastric Cancer Intervention:   Drug: Capecitabine, camrelizumab Sponsor:   Ruijin Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Hormone Receptor Positive Breast Carcinoma;   HER2-negative Breast Cancer Intervention:   Drug: OP-1250 Sponsor:   Olema Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackgroundCisplatin plus S-1 (CS) is the standard first-line chemotherapy for advanced gastric cancer (AGC) in Japan. A previous phase III trial showed that docetaxel plus S-1 (DS) was effective for AGC without measurable lesions, but no studies have compared these two regimens.MethodsEligible patients had unresectable or recurrent HER2-negative AGC without measurable lesions. Patients were randomized to DS (docetaxel 40  mg/m2 on day 1, S-1 80 –120 mg on days 1–14, every 3 weeks) or CS (cisplatin 60 mg/m2 on day 8, S-1 80 –120 mg on days 1–21, every 5 weeks). T...
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
Conditions:   Breast Cancer;   HER2-negative Breast Cancer;   ER Positive Breast Cancer;   ER-Negative Breast Cancer Interventions:   Drug: Infigratinib;   Drug: Tamoxifen;   Drug: Fulvestrant;   Drug: Palbociclib;   Drug: Omnipaque 350;   Drug: Iopamidol Sponsors:   Stanford University;   National Cancer Institute (NCI);   QED Therapeutics, Inc.;   Breast Cancer Research Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Discussion: The aim of this trial is to evaluate the safety and efficacy of combination therapy with trastuzumab and pertuzumab in patients with locally advanced or metastatic, solid cancers harboring HER2 amplification. Instead of focusing on 1 organ type, our trial design uses a basket study focusing on HER2 amplification, regardless of the site or origin of the cancer. The results of our study will advance clinical and scientific knowledge concerning the treatment of locally advanced, rare solid cancers harboring HER2 amplification, using the combination of trastuzumab and pertuzumab. Trial registration: This trial...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Condition:   HER2-Positive Solid Tumors Interventions:   Drug: Chort 1 of M802;   Drug: Chort 2 of M802;   Drug: Cohort 3 of M802;   Drug: Cohort 4 of M802;   Drug: Cohort 5 of M802;   Drug: Cohort 6 of M802;   Drug: Cohort 7 of M802;   Drug: Cohort 8 of M802 Sponsor:   Wuhan YZY Biopharma Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | HER2 | Neurology | Students | Universities & Medical Training